ClinicalTrials.gg

Program

peginterferon alfa-2b

Also written as “Peginterferon alfa-2b”, “peginterferon alfa-2b (SCH 54031)” and “PEG-Intron”.

Its studies are mostly in Hepatitis C, Chronic · Hepatitis C · Hepatitis B, Chronic · Melanoma · Hepatitis B, led by 4 companies.

Furthest: phase 4, since Nov 15, 200552 company-led studies, 2 open or runningNext primary completion: May 31, 2029

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck450 open or runningphase 4since Nov 15, 2005Mar 29, 2000none ahead
Tanabe Pharma30 open or runningphase 3since Nov 2, 2011Feb 24, 2008none ahead
Xiamen Amoytop Biotech32 open or runningphase 3since Apr 12, 2021Apr 12, 2021May 31, 2029NCT06707922
FGK Clinical Research10 open or runningphase 4since Jul 11, 2006Jul 11, 2006none ahead

Also a collaborator on its studies: Vertex Pharmaceuticals, Integrated Therapeutics Group, Johnson & Johnson and ViroPharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 35 studies since Mar 29, 2000.

  1. May 1, 2012Phase 3 study in Hepatitis C, ChronicMerck · NCT01590225
  2. May 24, 2012Phase 4 study in Hepatitis C, ChronicMerck · NCT01606800 · 45 enrolled
  3. Jul 5, 2012Phase 1 study in MelanomaMerck · NCT01636960 · 9 enrolled
  4. Jul 11, 20122 phase 3 studiesMerck · NCT01641926, NCT01641666
  5. Aug 30, 2012Phase 1 study in Hepatitis C, ChronicMerck · NCT01678131 · 31 enrolled
  6. Nov 12, 2012Phase 4 study in Hepatitis BMerck · NCT01727271
  7. Sep 13, 2013Phase 3 study in Hepatitis C, ChronicMerck · NCT01945294 · 257 enrolled
  8. Mar 14, 2014Phase 2 study in Carcinoma, Renal CellMerck · NCT02089685 · 295 enrolled
  9. Jun 2, 2014Phase 2 study in MelanomaMerck · NCT02155322 · 33 enrolled
  10. May 15, 20183 phase 3 studiesMerck · NCT03537274, NCT03547154, NCT03552549
  11. May 31, 2018Phase 1 study in NeoplasmsMerck · NCT03554005 · 29 enrolled
  12. Apr 12, 2021Xiamen Amoytop Biotech’s first study: phase 3 study in Hepatitis B, ChronicNew to Xiamen Amoytop BiotechXiamen Amoytop Biotech · NCT04846491 · 475 enrolled · China
  13. Jul 27, 2024Phase 2 study in Thrombocythemia, EssentialXiamen Amoytop Biotech · NCT06552429 · 27 planned · China
  14. Nov 24, 2024No phase study in Hepatitis B, ChronicXiamen Amoytop Biotech · NCT06707922 · 350 planned · China

Ahead

  1. May 31, 2029Primary completion: no phase study in Hepatitis B, ChronicXiamen Amoytop Biotech · NCT06707922

TargetBeta

“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
peginterferon alfa-2aruleHoffmann-La Rochephase 4100
Interferon beta-1aruleBiogenphase 460

Studies

All 52 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06707922Hepatitis B, Chronic · China–By invitationXiamen Amoytop BiotechMay 31, 2029350
NCT06552429Thrombocythemia, Essential · China2RecruitingXiamen Amoytop BiotechOct 26, 202527
NCT04846491Hepatitis B, Chronic · China3CompletedXiamen Amoytop BiotechNov 30, 2023475
NCT03554005Neoplasms1CompletedMerckMar 16, 200129
NCT03552549Melanoma3TerminatedMerckFeb 19, 2001126
NCT03547154Leukemia, Myelogenous, Chronic, BCR-ABL Positive3TerminatedMerckFeb 20, 2001344
NCT03537274Hepatitis C3CompletedMerckJul 23, 19991,224
NCT02155322Melanoma2CompletedMerckMar 21, 201633
NCT02089685Carcinoma, Renal Cell2CompletedMerckApr 1, 2021295
NCT01945294Hepatitis C, Chronic3CompletedMerckAug 5, 2015257
NCT01727271Hepatitis B4WithdrawnMerckAug 20170
NCT01678131Hepatitis C, Chronic1CompletedMerckAug 27, 201331
NCT01641926Hepatitis B, Chronic3TerminatedMerckJan 21, 2016402
NCT01641666Hepatitis C, Chronic3WithdrawnMerckSep 20160
NCT01636960Melanoma1TerminatedMerckMar 26, 20149
NCT01606800Hepatitis C, Chronic4TerminatedMerckJan 26, 201545
NCT01590225Hepatitis C, Chronic3WithdrawnMerckAug 18, 20210
NCT01547312Hepatitis C, Chronic1WithdrawnMerckNov 20120
NCT01468584Hepatitis C, Chronic · Japan3CompletedTanabe PharmaSep 201310
NCT01466192Hepatitis C, Chronic · Japan3CompletedTanabe PharmaAug 2013108
NCT01432535Renal Insufficiency1CompletedMerckAug 201225
NCT01081158Hepatitis C, Chronic1CompletedMerckAug 200841
NCT00811967Hepatitis C, Chronic3TerminatedMerckMay 200650
NCT00787371Hepatitis C, Chronic2CompletedMerckJul 200669
NCT00761735Hepatitis C, Chronic3CompletedMerckJan 201394
NCT00759109Carcinoma, Hepatocellular3CompletedMerckNov 2009150
NCT00724620Hepatitis C, Chronic4CompletedMerckFeb 2008103
NCT00687544Hepatitis C, Chronic4TerminatedMerckSep 200811
NCT00687219Hepatitis C, Chronic3CompletedMerckOct 2010102
NCT00686881Hepatitis C, Chronic3TerminatedMerckFeb 2011261
NCT00686790Hepatitis D, Chronic3CompletedMerckMay 200968
NCT00686777Hepatitis C, Chronic4CompletedMerckDec 201075
NCT00686517Hepatitis C3CompletedMerckDec 2010130
NCT00630058Hepatitis C · Japan1CompletedTanabe PharmaMar 200920
NCT00536263Hepatitis B, Chronic3CompletedMerckNov 2009671
NCT00493805Hepatitis C, Chronic4TerminatedMerckOct 200959
NCT00457418Melanoma1CompletedMerckMay 27, 200832
NCT00441584Hepatitis C, Chronic3TerminatedMerckJun 2008117
NCT00423800Hepatitis C, Chronic3TerminatedMerckOct 200956
NCT00381017Hepatitis C3WithdrawnMerck0
NCT00378599Hepatitis C, Chronic3CompletedMerckJul 2009125
NCT00371761Hepatitis B3CompletedMerckFeb 200925
NCT00351403Hepatitis C, Chronic · Germany4CompletedFGK Clinical ResearchJan 2010390
NCT00302081Hepatitis C, Chronic3CompletedMerckApr 2008696
NCT00265395Hepatitis C, Chronic3CompletedMerckMay 20081,428
NCT00255034Hepatitis C, Chronic4TerminatedMerckJun 2008146
NCT00237484Hepatitis C, Chronic3CompletedMerckJun 30, 201189
NCT00104052Hepatitis C, Chronic3CompletedMerckNov 2007107
NCT00049842Hepatitis C, Chronic3CompletedMerckOct 2009540
NCT00048724Hepatitis C, Chronic3CompletedMerckApr 2008631
NCT00035360HIV Infections3CompletedMerckOct 200349
NCT00005012HIV Infections · United States, Puerto Rico2CompletedMerck250

How it is read

Names in the registry

  • “Peginterferon alfa-2b”, 10 entries
  • “peginterferon alfa-2b (SCH 54031)”, 5 entries
  • “PEG-Intron”, 4 entries
  • “PegIntron (peginterferon alfa-2b)”, 4 entries
  • “Peginterferon alfa-2b injection”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.